Does route of administration affect the outcome of TNF antagonist therapy?

Arthritis Research & Therapy
Sergio Schwartzman, G James Morgan

Abstract

The tumor necrosis factor (TNF) antagonists are parenterally administered biologic response modifiers indicated for the management of rheumatoid arthritis. Although infliximab, etanercept, and adalimumab are all members of this class, they differ in route of administration and dosing regimen. In the USA and in Europe, infliximab, in combination with oral methotrexate, is administered intravenously, initially at a dose of 3 mg/kg at weeks 0, 2, and 6, then every 8 weeks thereafter. The US Food and Drug Administration (FDA) has further approved that the dosage can be increased to 10 mg/kg and the doses can be given as often as every 4 weeks to optimize patient outcome (information based on the US package insert dated June 2002). Etanercept and adalimumab are given subcutaneously and can be self-injected. The FDA-approved dose of etanercept is 25 mg twice weekly, and of adalimumab is 40 mg every 2 weeks with methotrexate, or 40 mg alone. Medication adherence, possibly the most important factor in maintaining the benefits of anti-TNF therapy, is influenced by the interaction between the patient and his or her healthcare team, the patient's attitude toward the disease and medication regimen, and the choice of therapy.

References

Mar 1, 1993·Current Opinion in Rheumatology·G J Morgan, W S Chow
Jul 6, 2000·Clinical Pediatrics·M L WinkelsteinC Rand
Nov 7, 2000·Journal of Pharmaceutical Sciences·S Porter
Nov 30, 2000·The New England Journal of Medicine·J M BathonB K Finck
Nov 30, 2000·The New England Journal of Medicine·P E LipskyUNKNOWN Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group
Jul 3, 2002·Pediatrics·UNKNOWN Committee on Drugs. American Academy of Pediatrics
Nov 5, 2002·The European Respiratory Journal·C E Kuehni, U Frey

❮ Previous
Next ❯

Citations

Mar 2, 2006·Arthritis Research & Therapy·Juan J Gomez-ReinoUNKNOWN BIOBADASER Group
Sep 1, 2012·Patient Preference and Adherence·Anshuman P Malaviya, Andrew Jk Ostör
Aug 3, 2010·International Journal of Clinical Rheumatology·Sofia de Achaval, Maria E Suarez-Almazor
Jan 12, 2010·Expert Opinion on Biological Therapy·Joaquín Borrás-BlascoF Javier Abad
May 6, 2011·Scandinavian Journal of Rheumatology. Supplement·F Buttgereit
Aug 4, 2011·Current Medical Research and Opinion·David T RubinAnne M Robinson
Nov 2, 2016·Expert Opinion on Drug Delivery·Barbara DomańskaMichael Schiff
Aug 5, 2017·Journal of the European Academy of Dermatology and Venereology : JEADV·D J LewisS R Feldman
Aug 30, 2007·Musculoskeletal Care·Frances Chilton, Raymond A Collett
Sep 18, 2018·Arthritis Care & Research·Lucas GrisantiNorman Gaylis
Aug 28, 2019·Journal of the European Academy of Dermatology and Venereology : JEADV·L EicherA Wollenberg
Oct 14, 2009·International Journal of Immunopathology and Pharmacology·F LicastroE Porcellini
Jul 10, 2010·International Journal of Qualitative Studies on Health and Well-being·Ingrid LarssonBarbro Arvidsson
Mar 4, 2020·Advances in Therapy·Kathryn BaileyBoglarka Szegvari

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.